Mesoblast has been making some waves and is set for some big time news. It is an Aussie biotech dual-listed as MESO on NASDAQ and MSB on ASX (primary). The usual biotech risks seem to have dissipated significantly, however they don't yet have a single approved product on the market. The stock has been the darling of shorters for nearly a decade now.

Key initiatives and Upcoming Milestones for the Next Two Quarters

Remestemcel-L • In the treatment of steroid-refractory acute graft versus host disease (SR-GVHD) in children, Mesoblast plans to discuss with CBER’s review team at the OTAT our approach to address certain outstanding CMC items, including potency assay validation.

Rexlemestrocel-L • Mesoblast intends to meet with FDA to discuss a potential pathway for approval of rexlemestrocel-L in patients with chronic discogenic lower back pain based on the observed durable reduction in pain and opioid sparing activity in the CLBP Phase 3 trial